Luteal Phase Support With GnRH Agonist Alone After GnRH Agonist Triggering and Fresh Embryo Transfer Compared to the Reference Protocol (hCG Triggering and Progesterone Luteal Support): a Randomised Controlled Trial
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
• Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.
• Patients aged 18 to 39 included
• First or second attempt at IVF or ICSI for pregnancy
• BMI \< 35 kg/m2
• Anti-Mullerian hormone (AMH) \> 1 ng/ml (= 7 pmol/L) and/or antral follicle count ≥ 8 within the year prior to inclusion
• AMH \< 5 ng/ml and/or antral follicle count \<40 within the year prior to inclusion
• Treatment with recombinant FSH
• Antagonist protocol (with pre-treatment or not)
• Initial dose of recombinant FSH between 75 and 450 IU
• Signed informed consent
• Affiliation to the social security system (excluding AME)